1. NF-κB
  2. NF-κB


Cat. No.: HY-13982 Purity: 99.10%
Handling Instructions

JSH-23 is an inhibitor of NF-κB with an IC50 value of 7.1 μM.

For research use only. We do not sell to patients.
JSH-23 Chemical Structure

JSH-23 Chemical Structure

CAS No. : 749886-87-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 117 In-stock
5 mg USD 106 In-stock
10 mg USD 190 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

    JSH-23 purchased from MCE. Usage Cited in: PLoS One. 2016 Nov 16;11(11):e0166740.

    HG-induced apoptosis in neonatal rat cardiomyocytes is mediated by activation of the NF-κB pathway. (A-B). Neonatal rat cardiomyocytes are pretreated with 10–20 μM JSH-23 and exposed to HG for 36 h. Levels of caspase-3 and cleaved caspase-3 and Bax/Bcl-2 ratios are determined by western blotting.

    JSH-23 purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2017;10(6):6544-6551.

    JSH-23 is added into MDA-MB-231 cells with the dose of 0 μmol, 1 μmol, 5 μmol when the cell planking density reaches about 60%. Then samples incubated for 24 h are collected when the cell density reaches about 80% and confirmed by western blot.

    JSH-23 purchased from MCE. Usage Cited in: Cancer Lett. 2018 Apr 27;428:77-89.

    Western blots show that the NF-κB inhibitors BAY11-7082, Parthenolide, and JSH-23 cause dramatic time- and dose-dependent reductions in MGMT protein expression in LN18 and T98G glioma cells.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    JSH-23 is an inhibitor of NF-κB with an IC50 value of 7.1 μM.

    IC50 & Target[1]


    7.1 μM (IC50)

    In Vitro

    JSH-23 inhibits LPS-induced chromatin condensation in a dose-dependent manner, corresponding to 44±4% inhibition at 3 μM, 63±5% at 10 μM and 93±3% at 30 μM[1]. JSH-23 (5, 10, and 15 μM) significantly reduces mean neuronal migration in LPS-activated cells[2]. Co-treatment of A2780 cells with JSH-23 and clinically ineffective transplatin at their IC50 concentrations (130 μM transplatin and 20 μM JSH-23) for 72 h also causes a more pronounced decrease in cell viability compared to the effects of transplatin or JSH-23 alone[3].

    In Vivo

    JSH-23 (1 and 3 mg/kg, p.o.) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic animals and decreases the nerve lipid peroxidation, partially replenishes the depleted levels of GSH in nerve of diabetic rats[4].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 4.1608 mL 20.8039 mL 41.6077 mL
    5 mM 0.8322 mL 4.1608 mL 8.3215 mL
    10 mM 0.4161 mL 2.0804 mL 4.1608 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    Apoptosis is analyzed by 4',6-diamidino-2-phenylindole (DAPI) staining. Macrophages RAW 264.7 incubated with JSH-23 are treated with 1 μg/mL LPS and/or sample for 24 h. The cells are stained with 1 μg/mL DAPI for 30 min at 37°C and then analyzed using fluorescence microscopy with excitation at 300-500 nm. Cells with nuclei containing clearly condensed chromatin or cells with fragmented nuclei are scored as an apoptosis index. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    JSH-23 is formulated in 0.5% sodium carboxymethyl cellulose.

    Male Sprague Dawley rats (250-270 g) are used and fed on standard rat diet and water ad libitum. Diabetes is induced by single dose of streptozotocin (STZ, 55 mg/kg, intraperitoneally) in citrate buffer. Blood samples are collected 48 h after STZ administration. Rats with plasma glucose level more than 250 mg/dL are considered as diabetics and are further considered for study. The experimental groups comprised of non-diabetic control rats (ND), diabetic control rats (STZ-D) and diabetic rats treated with two doses of JSH-23 (STZ-D + JSH 1 and STZ-D + JSH 3, respectively, for 1 and 3 mg/kg, orally in 0.5% sodium carboxymethyl cellulose). After 6 weeks of diabetes induction, the drug is administered daily for a period of 2 weeks. The functional, behavioural and biochemical experiments are performed 24 h after the administration of last dose. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 56 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: